Filtered By:
Condition: Heart Failure
Management: Hospitals

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 519 results found since Jan 2013.

Tissue Inhibitor of Metalloproteinase-1 Is Increased in Chagasic Cardiomyopathy
Am J Trop Med Hyg. 2021 Jul 19:tpmd200401. doi: 10.4269/ajtmh.20-0401. Online ahead of print.ABSTRACTChagas disease (CD) mainly conveys stroke risk through structural cardiac disease. However, stroke and cognitive impairment are seen in CD independently of cardiac disease severity. Chronic inflammation may be an explanation for this association, because inflammation plays an important role in the pathogenesis of acute ischemic stroke and dementia. In the present study, we selected five candidate biomarkers for Chagas disease: interleukin-6, membrane metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP1), oros...
Source: The American Journal of Tropical Medicine and Hygiene - July 19, 2021 Category: Tropical Medicine Authors: Karina Oliveira Garcia Thiago Cerqueira Silva Maria do Carmo Pereira Nunes Iuri Ferreira Felix Murilo Araujo Oliveira Maria Eduarda Lisboa Marques Leila Souza Brito Santos Paulo Roberto Sampaio Peixoto Sousa Pedro Jos é Ramiro Muiños Renata Martins Maia Source Type: research

There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist
Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2)  inhibitor versus a glucagon-like peptide-1 (GLP-1) receptor agonist. Background: Various studies have suggested that several SGLT2 inhibitors and GLP-1 receptor agonists may improve cardiac outcomes—myocardial infarction, stroke, hospitalization for heart failure, and cardiovascular death. Current guidelines recommend using either an SGLT2 inhibitor or GLP-1 receptor agonist for patients with type II diabetes and cardiovascular disease. However, there has been no st...
Source: The Hospitalist - September 1, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Diabetes Heart Failure In the Literature Source Type: research

Examination of Hospital Characteristics and Patient Quality Outcomes Using Four Inpatient Quality Indicators and 30-Day All-Cause Mortality
The study objective was to examine hospital mortality outcomes and structure using 2008 patient-level discharges from general community hospitals. Discharges from Florida administrative files were merged to the state mortality registry. A cross-sectional analysis of inpatient mortality was conducted using Inpatient Quality Indicators (IQIs) for acute myocardial infarction (AMI), congestive heart failure (CHF), stroke, pneumonia, and all-payer 30-day postdischarge mortality. Structural characteristics included bed size, volume, ownership, teaching status, and system affiliation. Outcomes were risk adjusted using 3M APR-DRG....
Source: American Journal of Medical Quality - January 3, 2013 Category: Health Management Authors: Carretta, H. J., Chukmaitov, A., Tang, A., Shin, J. Tags: Articles Source Type: research

Freedom in waiting: A ventricular assist device gives Aidan’s family independence
Aidan When Aidan was just 8 months old, his parents Patrick and Tavina received shocking news—their son had hypertrophic cardiomyopathy, a rare but serious disease that affects the muscle of the heart. Given his young age and severity of his condition, the early prognosis was bleak. “Things didn’t look good at first,” remembers Patrick. “We were steeling ourselves for the real possibility that Aidan wouldn’t make it to see his first birthday.” But, heart condition or not, little Aidan was a fighter, and with minimal medical management his condition stabilized. Over the years, he grew ...
Source: Thrive, Children's Hospital Boston - July 3, 2013 Category: Pediatrics Authors: Tripp Underwood Tags: All posts Heart conditions Our patients’ stories Christina VanderPluym Heart Center heart transplant hypertrophic cardiomyopathy MD VAD ventricular assist device Source Type: news

Understanding Digoxin
 Most of us have heard of, or encountered a patient taking Digoxin at some point in our carreers. But, do we understand what it is and how it affects our patient?    Digoxin (Lanoxin), is a Cardiac Glycoside, derived from the foxglove plant, Digitalis. This medication is often seen in the pre-hospital setting, used for the treatment of:    Heart Failure (HF) with reduced Systolic Function   Atrial Fibrillation (AF) and Atrial Flutter (A-flutter) associated with Rapid Ventricular Response (RVR)   Cardiomyopathies   Often combined with Calcium and Beta Channel Blockers, Angiot...
Source: EMS 12-Lead - January 10, 2014 Category: Cardiology Authors: Ivan Rios Tags: Atrial Fibrillation Bidirectional Ventricular Tachycardia Digoxin Digoxin toxicity Heart Failure Source Type: research

30-Year Trends in Patient Characteristics, Treatment Practices, and Long-Term Outcomes of Adults Aged 35 to 54 Years Hospitalized With Acute Myocardial Infarction
The objectives of our population-based study were to describe>3-decade-long trends in the clinical features, treatment practices, and long-term outcomes of young adults aged 35 to 54 years discharged from the hospital after AMI. The study population consisted of 2,142 residents of the Worcester (Massachusetts) metropolitan area who were hospitalized with AMI at all central Massachusetts medical centers during 16 annual periods from 1975 to 2007. Our primarily male study population had an average age of 47 years. Patients hospitalized during the most recent decade (1997 to 2007) under study were more likely to have a hist...
Source: The American Journal of Cardiology - January 15, 2014 Category: Cardiology Authors: Mayra Tisminetzky, David D. McManus, Joel M. Gore, Jorge Yarzebski, Andrew Coles, Darleen Lessard, Robert J. Goldberg Tags: Coronary Artery Disease Source Type: research

Infective endocarditis: old problem, new guidelines and still much to learn
Despite major advances in treating valvular heart disease, the in-hospital mortality (15–20%) and 1-year mortality (~=40%) for infective endocarditis (IE) has not improved even with modern antibiotics and surgical therapy. Further, stroke (17%), embolisation other than stroke (23%), heart failure (HF) (32%) and other complications remain common; therefore, all precautions to help prevent IE should be employed where indicated. In underdeveloped countries, IE is most often associated with rheumatic heart disease. In developed countries, IE is increasingly associated with prosthetic valves and intracardiac devices, with...
Source: Heart - June 9, 2014 Category: Cardiology Authors: Erwin, J. P., Otto, C. M. Tags: Drugs: cardiovascular system, Echocardiography, Clinical diagnostic tests, Epidemiology, Diabetes, Metabolic disorders Editorials Source Type: research

The value of CHADS score in predicting new-onset atrial fibrillation in Chinese patients with acute myocardial infarction
Previous studies have shown that new-onset atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) was associated with increased in-hospital and long term mortality [1,2]. Therefore, it was crucial to recognize the patients with AMI who were on the increased risk for developing new-onset AF. CHADS2 score (congestive heart failure, hypertension, age≥75years, diabetes and previous stroke or transient ischemic attack) was a very useful and convenient scoring system, which was widely used for the stroke risk stratification in the patients with non-valvular AF [3].
Source: International Journal of Cardiology - August 5, 2014 Category: Cardiology Authors: Xiaowei Zhang, Guangping Li, Zhiqiang Zhao, Yanmin Xu, Tong Liu Source Type: research

The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry
Abstract The aim of the study was to determine the influence of the previous use of digoxin on the hospital mortality and complications of patients admitted because of acute coronary syndrome (ACS). We analyzed the data of patients included in the ARIAM-Andalucia Registry, which involves 49 hospitals in Andalucia, Spain, from 2007 to 2012. Patients on digoxin treatment prior to their admission because of ACS constituted the digoxin group (DG), and were compared with the group of patients not on digoxin. Logistic regression and propensity score matching were used to analyze the differences. We included 20,331 ...
Source: Internal and Emergency Medicine - October 1, 2014 Category: Emergency Medicine Source Type: research

Clinical characteristics, hospital care, and prognosis of patients with ST elevation myocardial infarction: Hungarian Myocardial Infarction Registry
The authors analyse clinical data, hospital care, and short- and long-term prognosis of 4981 ST segment elevation myocardial infarction (STEMI) patients enrolled in the web-based Hungarian Myocardial Infarction Registry. It has been found that the mean age of STEMI patients was lower by 5.3 years than that of patients treated for non-STEMI (NSTEMI). In the group of NSTEMI patients (n = 3601), the occurrence of diabetes, hypertension, peripheral vascular disease, and previous history of myocardial infarction and stroke were significantly more frequent. The proportion of smokers among STEMI patients was remarkably higher. Pr...
Source: European Journal of Heart Failure Supplements - January 10, 2014 Category: Cardiology Authors: Janosi, A., Ofner, P., Forster, T., Edes, I., Toth, K., Merkely, B. Tags: Articles Source Type: research